Hancock Jaffe Laboratories, Inc. (HJLI): Price and Financial Metrics

Hancock Jaffe Laboratories, Inc. (HJLI)

Today's Latest Price: $8.02 USD

0.63 (8.53%)

Updated Dec 1 3:59pm

Add HJLI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

HJLI Stock Summary

  • Hancock Jaffe Laboratories Inc's market capitalization of $7,135,019 is ahead of just 3.84% of US-listed equities.
  • HJLI's price/sales ratio is 228.37; that's higher than the P/S ratio of 98.53% of US stocks.
  • As for revenue growth, note that HJLI's revenue has grown -83.25% over the past 12 months; that beats the revenue growth of just 1.36% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Hancock Jaffe Laboratories Inc are MOTS, NBRV, KALA, RKDA, and ADMP.
  • Visit HJLI's SEC page to see the company's official filings. To visit the company's web site, go to www.hancockjaffe.com.

HJLI Stock Price Chart Interactive Chart >

Price chart for HJLI

HJLI Price/Volume Stats

Current price $8.02 52-week high $21.25
Prev. close $7.39 52-week low $5.28
Day low $7.40 Volume 396,700
Day high $8.90 Avg. volume 159,909
50-day MA $9.20 Dividend yield N/A
200-day MA $9.89 Market Cap 17.92M

Hancock Jaffe Laboratories, Inc. (HJLI) Company Bio

Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is based in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.

HJLI Latest News Stream

Event/Time News Detail
Loading, please wait...

HJLI Latest Social Stream

Loading social stream, please wait...

View Full HJLI Social Stream

Latest HJLI News From Around the Web

Below are the latest news stories about Hancock Jaffe Laboratories Inc that investors may wish to consider to help them evaluate HJLI as an investment opportunity.

GEVO, GME, TOPS and BKE among midday movers

Gainers: Hancock Jaffe Laboratories (HJLI) +127%.Harpoon Therapeutics (HARP) +38%.ShiftPixy (PIXY) +22%.Velocity Financial (VEL) +21%.The Buckle (BKE) +20%.GameStop (GME) +19%.CLPS (CLPS) +19%.Cryoport (CYRX) +17%.Kirkland's (KIRK) +16%.Cambium Networks (CMBM) +15%.Losers: The Cato (CATO) -26%.Gevo (GEVO) -25%.Top Ships (TOPS) -20%.VivoPower International (VVPR) -20%.GAN (GAN) -16%.Hudson Technologies (HDSN) -16%.Akers Biosciences (AKER) -14%.MICT (MICT) -13%.Koss (KOSS) -12%.AMTD International (HKIB) -9%....

Seeking Alpha | August 21, 2020

Hancock Jaffe Laboratories leads healthcare gainers: Organovo leads the losers

Gainers: Hancock Jaffe Laboratories (HJLI) +83%. Bio-Path Holdings (BPTH) +22%. Harpoon Therapeutics (HARP) +21%. Fluidigm (FLDM) +15%. Midatech Pharma (MTP) +13%.Losers: Organovo (ONVO) -10%. Akers Biosciences (AKER) -9%. Trevena (TRVN) -9%. OpGen (OPGN) -9%. Axcella Health (AXLA) -7%....

Seeking Alpha | August 21, 2020

Hancock Jaffe Announces One Year Follow-up Data on Two Additional VenoValve Patients

VenoValve Patients Continue to Show Significant Improvement at One YearIRVINE, CA / ACCESSWIRE / August 21, 2020 / Hancock Jaffe Laboratories, Inc.

Yahoo Finance | August 21, 2020

Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study

Patient Selection to Begin Immediately for CoreoGraft Study IRVINE, CA / ACCESSWIRE / July 23, 2020 / Hancock Jaffe Laboratories, Inc.

Yahoo | July 23, 2020

Hancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment Option

IRVINE, CA / ACCESSWIRE / July 21, 2020 / Hancock Jaffe Laboratories, Inc.

Yahoo | July 21, 2020

Read More 'HJLI' Stories Here

HJLI Price Returns

1-mo 1.49%
3-mo -17.36%
6-mo -13.62%
1-year -35.36%
3-year N/A
5-year N/A
YTD -41.67%
2019 -62.71%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching HJLI

Here are a few links from around the web to help you further your research on Hancock Jaffe Laboratories Inc's stock as an investment opportunity:

Hancock Jaffe Laboratories Inc (HJLI) Stock Price | Nasdaq
Hancock Jaffe Laboratories Inc (HJLI) Stock Quote, History and News - Yahoo Finance
Hancock Jaffe Laboratories Inc (HJLI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.711 seconds.